ACTU — Actuate Therapeutics Share News
0.000.00%
Last trade - 00:00H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating
Brief: Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation For Elraglusib For The Treatment Of Pancreatic Cancer
Brief: Actuate Therapeutics Announces Interim Phase 2 Data Of Elraglusib
Brief: Actuate Therapeutics To Be Added To Russell 2000 Index
Brief: Actuate Announces FDA Rare Pediatric Disease Designation Granted To Elraglusib For Treatment Of Ewing Sarcoma
Brief: Actuate Therapeutics Announces Closing Of IPO
Brief: Actuate Therapeutics Announces Pricing Of IPO
Brief: Actuate Therapeutics Files Registration Statement For IPO